Searched for
SHIONOGI
Pharma in her DNA, Wockhardt scion ready for deep dive in the USZahabiya Khorakiwala is leading Wockhardt's US business and the launch of its new antibiotic, Zaynich. This drug targets resistant bacteria...- GSK to buy RAPT Therapeutics in $2.2 billion deal for promising food allergy therapyBritain's GSK is set to acquire RAPT Therapeutics for $2.2 billion. This move brings the experimental food allergy drug ozureprubart into G...
- Japan's Topix index touches record high in tentative trade before Fed, BOJJapan's Topix stock index reached an unprecedented high on Wednesday before paring gains. Investors are closely watching central bank decis...
- Orchid all set to generate enough cash to fund expansion plans: Manish Dhanuka“Three years back, when we started, we had a significant debt. But, today we are a debt-free company and we also have significant investmen...
- Japanese shares edge higher despite surprise economic contractionAppetite for Japanese stocks is getting stronger as investors see them as a bargain," said Chihiro Ohta, assistant general manager, investm...
- Japan's Nikkei ends at near 3-month low on global recession fearsInvestors globally are on edge as surging borrowing costs stoke fears of widespread recession, with most of the world's major central banks...
- Japanese stocks gain as BOJ retains easy policy stanceThe Nikkei share average ended up 0.44% at 27,803, topping the six-week high reached the previous day. The broader Topix added 0.21% to 1,9...
- Covid pills are here, but they aren't for everyone. Find out if you should take this medicationThe pills have to be started as soon as possible, within five days of the start of symptoms.
- Nikkei sees biggest gain in over 3 weeks after US inflation dataThe Nikkei share average ended 1.93% higher at 26,843.49 - the biggest jump since March 22 - and marked a sharp rebound from its near four-...
- Japan's Nikkei posts longest winning streak in 2.5 yearsThe Nikkei share average reversed course to inch 0.14% higher to 28,149.84, with the index gaining 4.93% this week.
- Tech pushes Nikkei higher even as U.S. CPI caution prevails"Japanese shares rebounded as Nasdaq futures gained (in Asian trading hours), but the upside was capped because investors were cautious ahe...
- Tardy Covid vaccine makers under fire for trials in developing nationsVaccine developers only bringing shots to the testing phase now are finding it an uphill battle, with the developed world so highly vaccina...
- Japan's Nikkei ends higher on economic rebound hopes; Eisai drags TopixThe Nikkei share average ended 0.34 per cent higher at 28,958.56, while the broader Topix ticked down 0.02 per cent to 1,956.73.
- On World AIDS Day, South Africa finds hope in new treatmentA new drug, Cabotegravir, has been proven to be 90 per cent more effective than the daily pill known as PrEP against AIDS. Cabotegravir is ...
- Lupin arm buys branded drugs from Japan’s ShionogiThe new branded product portfolio has a strong fit with Lupin’s Kyowa business, as it adds depth and reach to its current CNS (central nerv...
- Lupin in talks with Japan's Astellas, Shionogi to buy their off-patent drug brandsThe acquisition will result in a wider offering for Lupin in Japanese market where its sales last fiscal stood at Rs 1,364 crore.
- AstraZeneca settles Crestor patent row with generics firmsAstraZeneca settleS a legal fight over its top-selling cholesterol drug Crestor with generics companies, protecting revenues in all importa...
- Lupin resumes anti-diabetic drug sales in US after court nodIn December last year, Shionogi's request for a preliminary injunction had been granted and had blocked Lupin from further sales of the pro...
- US court restrains Lupin from selling generic drug 'Fortamet'The US court, however, denied the motion of Shionogi for recall of Lupin's already distributed generic Fortamet during the two weeks of at-...
- Ranbaxy gets USFDA nod for generic version of ulcer drugDrug maker Ranbaxy Laboratories today said it has received approval from the US drug regulator for manufacturing and marketing the generic ...
Load More
